| abstract |
Disclosed are methods for treating conditions associated with hyperglycemia, especially type II diabetes, using new naphthylsulfonic acids and related compounds. The compounds of formula (I), where R and R independently represent hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R denotes the substituent in the ring and means-SOOR, -C (O) OR, -SONR, -C (O) NR or tetrazolyl; the linker -WY- between naphthyl and phenyl separates naphthyl ring A and means independently of each other -C (O) NR-, -NRC (O) -, -C (O) O-, -OC (O) -, -CH = CH-, -NRCH-, -CHNR-, -NRC (O) NR-, -NRC (O) O-, -OC (O) NR-, -NRSOO-, -OSONR-, -OC (O) O -, -SONR-, -NRSO-, -OSO-, or -SOO-; R3 and R4 are each independently hydrogen or (lower) alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or their pharmaceutically acceptable salts, are useful in methods for stimulating the kinase activity of the insulin receptor, enhancing insulin receptor activation by insulin, and stimulating the uptake of glucose by cells. A number of antidiabetic compounds and pharmaceutical formulations containing antidiabetic compounds are also disclosed. The international application was published along with an international search report. |